Case series demonstrates ensitrelvir administration for COVID-19 in hospitalized patients of very advanced age, highlighting the limited real-world clinical safety and effectiveness data.
Ensitrelvir fumaric acid (ensitrelvir) is an orally active 3C-like protease inhibitor used to treat severe acute respiratory syndrome coronavirus 2 infection. Ensitrelvir was granted an emergency use authorization in Japan in 2022, but reports on the effectiveness and safety of ensitrelvir in actual clinical settings are limited.
No takes yet. Share an insight, caveat, or question.
Tomita et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: